'Deeper And More Complex' – Nestlé CEO Bemoans VMS Supply Chain Problems

Supply problems for Nestlé’s US dietary supplement brands “were more fundamental than initially we have estimated,” according to CEO Mark Schneider. Nestlé now expects the issue – first flagged up last year – won’t be fully resolved until the end of the first half of 2024.

• Source: Shutterstock

Nestlé CEO Mark Schneider has conveyed his disappointment that supply chain problems impacting the firm’s vitamin, mineral and supplement sales in North America have not been resolved more quickly.

“I can only express my regrets,” he told the Swiss firm’s full year earnings call. “If you're sensing a certain...

Welcome to HBW Insight

Create an account to read this article

More from Supply Chain

Wellness Firms Targeting GLP-1 Patients’ Dietary Needs Keep Option To Provide Access To Oral Rx

Health and wellness brands and retail chains providing access to prescriptions for compounded GLP-1 drugs, most also offering supplements curated to help meet dietary needs of GLP-1 patients, are offering formulations in oral form as well as injection.

Over The Counter: EU Omnibus And ESG, What You Need To Know, With CEN Group’s Jasper Crone

 
• By 

HBW Insight catches up with sustainability expert Jasper Crone to find out what consumer health companies need to know about the European Commission's Omnibus simplification package.

US Consumer Health, Beauty Sectors: Expecting Tariff Policy Changes, Buckling Up For The Ride

 

As firms in OTC drug, dietary supplement and personal care/beauty sectors reported results for January-March period after Trump announced reciprocal tariffs, they buckled up for more changes in the president’s thinking likely to affect consumer spending as well as their costs.

OTC Drug, Supplement Trade Groups Argue For Tariff Exemption, International Supply Chain

 

Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.

More from HBW Insight

Democrats Slam Trump’s ‘Sledgehammer’ On FDA

 

“We cannot ignore how Trump has taken a sledgehammer to the FDA ability to evaluate new drugs,” says California’s Nanette Diaz Barragán of California during Energy and Comme e markup discussion of five-year reauthorization of FDA’s OMUFA.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.

Reckitt Leans On Europe As It Resets Mucinex In US

 
• By 

Decision to reformulate Mucinex sinus products without phenylephrine hits Reckitt's Q2 sales but the firm says it is preparing for upcoming cold & flu season with new marketing push.